Floatz logo

Dc-Cik

Squamous Cell Carcinoma

Tianjin Medical University Cancer Institute and HospitalCell therapyPhase 2/3Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Neonc Technologies, Inc.
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Oxford
Phase 3BB
Cyclophosphamide
Diwakar Davar
Phase 2B
Epirubicin
Diwakar Davar
Phase 2B
Pembrolizumab
Diwakar Davar
Phase 2B

View all 50 →

Same molecule, other indications

Dc-Cik is also rated in:

Postoperative ComplicationsDormant
BB
Indicative ·
67 / 100
View asset →
Cytokine-induced Killer CellsDormant
BB
Indicative ·
67 / 100
View asset →
Multiple Drug UseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →